DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Krishna S, White, NJ. Pharmacokinetics of quinine, chloroquine
and amodiaquine. Clinical implications. Clin Pharmacokinet,
1996, 30:263–299.
Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil
therapy for Plasmodium falciparum and Plasmodium vivax
malaria in Indonesians who lack clinical immunity. Clin Infect
Dis, 2002, 35:e92–95.
Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebocontrolled
trial of atovaquone/proguanil for the prevention
of Plasmodium falciparum or Plasmodium vivax malaria
among migrants to Papua, Indonesia. Clin Infect Dis, 2002,
35:825–833.
Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB.
Malarone (atovaquone and proguanil hydrochloride): A review
of its clinical development for treatment of malaria. Malarone
Clinical Trials Study Group. Am J Trop Med Hyg, 1999,
60:533–541.
Lozovsky ER, Chookajorn T, Brown KM, et al. Stepwise acquisition
of pyrimethamine resistance in the malaria parasite.
Proc Natl Acad Sci USA, 2009, 106:12025–12030.
Martin RE, Marchetti RV, Cowan AI, et al. Chloroquine transport
via the malaria parasite’s chloroquine resistance transporter.
Science, 2009, 325:1680–1682.
McGready R, Tan SO, Ashley EA, et al. A randomised controlled
trial of artemether-lumefantrine versus artesunate for uncomplicated
plasmodium falciparum treatment in pregnancy. PLoS
Med, 2008, 5:e253.
Medhi B, Patyar S, Rao RS, et al. Pharmacokinetic and toxicological
profile of artemisinin compounds: An update.
Pharmacology, 2009, 84:323–332.
Ménard D, Barnadas C, Bouchier C, et al. Plasmodium vivax
clinical malaria is commonly observed in Duffy-negative
Malagasy people. Proc Natl Acad Sci, 2010, 107:5967–5971.
Miller KD, Greenberg AE, Campbell CC. Treatment of severe
malaria in the United States with a continuous infusion of
quinidine gluconate and exchange transfusion. N Engl J Med,
1989, 321:65–70.
Musset L, Bouchaud O, Matheron S, et al. Clinical atovaquoneproguanil
resistance of Plasmodium falciparum associated
with cytochrome b codon 268 mutations. Microbes Infect,
2006, 8:2599–2604.
Nair S, Miller B, Barends M, et al. Adaptive copy number evolution
in malaria parasites. PLoS Genet, 2008, 4:e1000243.
Nkrumah LJ, Riegelhaupt PM, Moura P, et al. Probing the multifactorial
basis of Plasmodium falciparum quinine resistance:
Evidence for a strain-specific contribution of the sodium-proton
exchanger PfNHE. Mol Biochem Parasitol, 2009, 165:
122–131.
Olliaro P, Mussano P. Amodiaquine for treating malaria.
Cochrane Database Syst Rev, 2003, CD000016.
Olliaro P, Wells TN. The global portfolio of new antimalarial
medicines under development. Clin Pharmacol Ther, 2009,
85:584–595.
Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role
of mitochondrial electron transport in blood-stage Plasmodium
falciparum. Nature, 2007, 446:88–91.
Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential
resistance to cycloguanil and pyrimethamine in
Plasmodium falciparum malaria. Proc Natl Acad Sci USA,
1990, 87:3018–3022.
Price RN, Douglas NM, Anstey NM. New developments in
Plasmodium vivax malaria: Severe disease and the rise of chloroquine
resistance. Curr Opin Infect Dis, 2009, 22:430–435.
Price RN, Uhlemann A-C, Brockman A, et al. Mefloquine resistance
in Plasmodium falciparum and increased pfmdr1 gene
copy number. Lancet, 2004, 364:438–447.
Raj DK, Mu J, Jiang H, et al. Disruption of a Plasmodium falciparum
multidrug resistance-associated protein (PfMRP) alters
its fitness and transport of antimalarial drugs and glutathione.
J Biol Chem, 2009, 284:7687–7696.
Rennie IG. Clinically important ocular reactions to systemic drug
therapy. Drug Saf, 1993, 9:196–211.
Rocco F. The Miraculous Fever-Tree: Malaria and the Quest for a
Cure That Changed the World. HarperCollins, New York, 2003.
Rohrbach P, Sanchez CP, Hayton K, et al. Genetic linkage of
pfmdr1 with food vacuolar solute import in Plasmodium falciparum.
EMBO J, 2006, 25:3000–3011.
Rose GW, Suh KN, Kain KC, et al. Atovaquone-proguanil resistance
in imported falciparum malaria in a young child. Pediatr
Infect Dis J, 2008, 27:567–569.
Rosenthal PJ. Artesunate for the treatment of severe falciparum
malaria. N Engl J Med, 2008, 358:1829–1836.
Sanchez CP, Rohrbach P, McLean JE, et al. Differences in transstimulated
chloroquine efflux kinetics are linked to PfCRT in
Plasmodium falciparum. Mol Microbiol, 2007, 64:407–420.
Schlagenhauf P, Petersen E. Malaria chemoprophylaxis: Strategies
for risk groups. Clin Microbiol Rev, 2008, 21:466–472.
Schlitzer M. Malaria chemotherapeutics part I: History of
antimalarial drug development, currently used therapeutics,
and drugs in clinical development. Chem Med Chem, 2007,
2:944–986.
Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance
in Plasmodium falciparum malaria parasites conferred by pfcrt
mutations. Science, 2002, 298:210–213.
Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations
contribute to quinine resistance and enhance mefloquine and
artemisinin sensitivity in Plasmodium falciparum. Mol
Microbiol, 2005, 57:913–926.
Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination
therapy for treating uncomplicated malaria. Cochrane
Database Syst Rev, 2009, CD007483.
Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of
Plasmodium falciparum parasites carrying the chloroquinesusceptible
pfcrt K76 allele after treatment with artemetherlumefantrine
in Africa. J Infect Dis, 2009, 199:750–757.
Srivastava IK, Morrisey JM, Darrouzet E, et al. Resistance mutations
reveal the atovaquone-binding domain of cytochrome b
in malaria parasites. Mol Microbiol, 1999, 33:704–711.
Sullivan DJ Jr, Matile H, Ridley RG, Goldberg DE. A common
mechanism for blockade of heme polymerization by antimalarial
quinolines. J Biol Chem, 1998, 273:31103–31107.
Taylor WR, White NJ. Antimalarial drug toxicity: A review.
Drug Saf, 2004, 27:25–61.
Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity
of hydroxychloroquine. Semin Ophthalmol, 2008, 23:201–209.
Thompson MJ, White N, Jong EC. Malaria diagnosis and treatment.
In: Malaria Diagnosis and Treatment (Jong EC, McMullen R,
eds.), Saunders, Philadelphia, 2003, 269–288.
Vaidya AB, Mather MW. Mitochondrial evolution and functions
in malaria parasites. Annu Rev Microbiol, 2009, 63:249–267.
1417
CHAPTER 49
CHEMOTHERAPY OF MALARIA